Omnicell, Inc. (NASDAQ:OMCL – Get Rating) stock price fell ahead of Wednesday’s market open. The stock had previously closed at $120.11, but opened at $115.01. Omnicell shares last traded at $111.39, with volume traded at 3,685 shares.
OMCL has been the subject of a number of research reports. StockNews.com launched coverage on Omnicell in a research report on Thursday, March 31. They have placed a “holding” rating on the stock. Piper Sandler lowered its price target on Omnicell from $181.00 to $162.00 in a Monday, May 2 research report. Wells Fargo & Company lowered its price target on Omnicell from $188.00 to $158.00 and set an “overweight” rating for the company in a Tuesday, May 3 research report. Finally, TheStreet downgraded Omnicell from a “b-” rating to a “c+” rating in a Tuesday, May 17 research report. One equity research analyst gave the stock a hold rating and four gave the company’s stock a buy rating. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $186.25.
The stock has a market capitalization of $5.03 billion, a PE ratio of 76.34, a growth price-earnings ratio of 2.23 and a beta of 1.21. The company has a 50-day moving average price of $112.23 and a 200-day moving average price of $134.06.
Omnicell (NASDAQ:OMCL – Get Rating) last announced its results on Thursday, April 28. The company reported earnings per share (EPS) of $0.53 for the quarter, beating the consensus estimate of $0.40 by $0.13. Omnicell had a return on equity of 11.35% and a net margin of 6.00%. The company posted revenue of $319.00 million in the quarter, versus analyst estimates of $313.98 million. During the same period last year, the company posted EPS of $0.62. The company’s revenues increased by 26.7% compared to the same quarter last year. On average, analysts expect Omnicell, Inc. to post earnings per share of 2.73 for the current year.
In other news, Executive Vice President Scott Peter Seidelmann sold 3,765 shares of the company in a trade on Thursday, June 16. The stock was sold at an average price of $110.15, for a total transaction of $414,714.75. Following the completion of the sale, the executive vice president now directly owns 40,789 shares of the company, valued at approximately $4,492,908.35. The sale was disclosed in a legal filing with the SEC, which is available on the SEC’s website. Insiders of the company hold 2.76% of the shares of the company.
Hedge funds have recently been buying and selling shares of the company. UBS Asset Management Americas Inc. increased its stake in Omnicell shares by 2.7% during the third quarter. UBS Asset Management Americas Inc. now owns 50,532 shares of the company worth $7,500,000 after acquiring an additional 1,323 shares during the period. Lindenwold Advisors bought a new position in Omnicell in Q4 worth around $377,000. Teacher Retirement System of Texas increased its stake in Omnicell by 24.5% in Q4. Teacher Retirement System of Texas now owns 8,644 shares of the company worth $1,560,000 after purchasing an additional 1,700 shares during the period. EAM Global Investors LLC bought a new position in Omnicell in Q4 worth approximately $2,783,000. Finally, Roubaix Capital LLC bought a new position in Omnicell in the 1st quarter for a value of approximately $2,583,000.
About Omnicell (NASDAQ: OMCL)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and compliance tools for healthcare systems and pharmacies in the United States and around the world. The company offers point-of-care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for the operating room; Omnicell interface software that provides interface and integration between its drug utilization or procurement products and a healthcare facility’s internal information management systems; and robotic dispensing systems to manage the storage and retrieval of boxed medications.
Featured articles
Get news and reviews for Omnicell Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Omnicell and related companies with MarketBeat.com’s free daily email newsletter.
Comments are closed.